CD274 and myelodysplastic syndrome: The ORR was merely improved in the PD-L1 inhibitor combination group versus the AZA monotherapy group (61.9% and 31.3% in the MDS and AML cohorts in the combination group, respectively, vs. 47.6% and 35.4% in the MDS and AML cohorts in the AZA alone group, respectively), whereas no improvement was found in median OS (11.6 and 13.0 months in MDS and AML patients in the combination group, respectively, vs. 16.7 and 14.4 months in MDS and AML patients in the AZA alone group) [134].